Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GZW
|
|||
| Former ID |
DCL000905
|
|||
| Drug Name |
ONO-2506
|
|||
| Synonyms |
(2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO; Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Stroke [ICD-11: 8B20; ICD-10: I64] | Phase 2/3 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Terminated | [2] | ||
| Company |
Ono Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H22O2
|
|||
| Canonical SMILES |
CCCCCCC(CCC)C(=O)O
|
|||
| InChI |
1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1
|
|||
| InChIKey |
YCYMCMYLORLIJX-SNVBAGLBSA-N
|
|||
| CAS Number |
CAS 185517-21-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9368737, 12015175, 15171440, 15195263, 30413566, 47207953, 57399566, 78156578, 103066752, 103079595, 113442118, 117541332, 124894576, 129777841, 132572103, 134339356, 134340030, 135183048, 135694756, 137061534, 142551269, 144206875, 162254961, 162807354, 163413958, 163884615, 164835957, 172859255, 175426981, 180371084, 198967322, 223545538, 224174346, 226396378, 242590696, 252158144, 252513052
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [3] |
| S100 calcium-binding protein B (S100B) | Target Info | Modulator | [4], [5] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Salivary secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta3 adrenergic receptor signaling pathway | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00229177) Study of ONO-2506 in Patients With Acute Ischemic Stroke. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008959) | |||
| REF 3 | FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12. | |||
| REF 4 | Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42. | |||
| REF 5 | S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.Clin Cancer Res.2013 Jul 15;19(14):3764-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.